• Atlantic Union Bankshares Corp significantly increases its investment in Amgen Inc. (NASDAQ: AMGN), showcasing strong investor confidence.
• Several firms, including Legacy Investment Solutions LLC and Evelyn Partners Investment Management LLP, have acquired new stakes in Amgen, indicating growing interest in the company's potential.
• Despite some investors reducing their holdings, Amgen's stock remains a significant part of portfolios, with the company maintaining a solid market capitalization of approximately $185 billion.

On January 29, 2026, David Taylor engaged in a sale transaction involving shares of Amgen Inc. (NASDAQ: AMGN), with the transaction amount ranging between $1,001 and $15,000. Amgen is a leading biotechnology company known for its innovative therapies and treatments. It operates in a competitive landscape with peers like Biogen and Gilead Sciences.

Atlantic Union Bankshares Corp has shown confidence in Amgen by increasing its investment by 66.3% in the third quarter. The firm now holds 17,698 shares, valued at approximately $5 million. This move aligns with a broader trend of large investors adjusting their positions in Amgen, as highlighted by several firms acquiring new stakes.

Legacy Investment Solutions LLC and Evelyn Partners Investment Management LLP have both acquired new stakes in Amgen, valued at around $27,000 and $32,000, respectively. Meanwhile, Quaker Wealth Management LLC increased its position by 200% in the second quarter. These actions indicate a growing interest in Amgen's potential.

Conversely, Atle Fund Management AB reduced its holdings in Amgen by 42.2% during the third quarter, now owning 13,806 shares. Despite this reduction, Amgen remains a significant part of their portfolio, valued at approximately $3.9 million. This highlights the varied strategies investors are employing with Amgen shares.

Amgen's stock is currently trading at $343.63, reflecting a slight decrease of $1.16 or -0.34% today. The stock has seen fluctuations, with a 52-week high of $353.25 and a low of $261.43. With a market capitalization of approximately $185 billion, Amgen remains a key player in the biotechnology sector.